Establishing a Tumor Bank and Initial Analysis of Germline and Tumor-Related Genetic Alterations in Families With Multiple Lymphoproliferative Malignancies

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

The purpose of this study is to investigate possible genetic factors that contribute to the development of lymphomas. The databank will be used to determine whether familial lymphomas have unique genetic characteristics different from sporadic lymphomas and to attempt to identify a gene that confers an increased risk of lymphoma.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Any individual diagnosed with non-Hodgkin's lymphoma or Hodgkin's disease or chronic lymphocytic leukemia (CLL), who has a 1st degree relative (parent, sibling or child) with a lymphoproliferative disorder; or families in which the individual has a lymphoproliferative disorder, and an unusual clustering of frequent or premature solid tumors is also observed.

• Family members of the individual, either affected or unaffected with lymphoma, who are contacted by the individual and agree to participate in the study.

• Deceased family members may be included in the study. Public records such as death certificates may be used to confirm the history. Consent for medical records or tissue blocks will be obtained from the deceased family member's next of kin. The hierarchy of relatives defined as next of kin is spouse, offspring, parents and siblings. Archived tissue samples may be used for genetic research.

• Age \> 18 years

Locations
United States
Massachusetts
Dana-Farber Cancer Institute
RECRUITING
Boston
Contact Information
Primary
Celeste Carey, MS
celeste_carey@dfci.harvard.edu
857-215-1646
Backup
Jennifer Brown, MD PhD
Jennifer_Brown@dfci.harvard.edu
617-632-4564
Time Frame
Start Date: 2004-08-09
Estimated Completion Date: 2033-01
Participants
Target number of participants: 1500
Treatments
Next of Kin of deceased subj by lymphoma
Next of Kin of deceased subject by lymphoma
Subject unaffected by lymphoma
Subject unaffected by lymphoma
Subject affected by lymphoma
Subject affected by lymphoma
Sponsors
Leads: Dana-Farber Cancer Institute

This content was sourced from clinicaltrials.gov